RxDoctor Payments Data

Jorge Martinez-Prieto, MD

Neurology · San Antonio, TXNPI 1447245469

Payments from drug & device makers

$23,281in general payments, 2019–2025

Across 1,446 payments — averaging $16.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$3K
  • UCB, Inc.$2K
  • Novartis$2K
  • Bristol Myers Squibb$2K
  • TG Therapeutics, Inc.$1K
  • Genentech USA, Inc.$1K
  • plus $13K from 52 others

What the payments were for

  • Food & beverage$23,202100%
  • Education$790%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
EMD Serono, Inc.175$2,723
UCB, Inc.98$2,037
Novartis121$1,725
Bristol Myers Squibb112$1,534
TG Therapeutics, Inc.82$1,412
Genentech USA, Inc.54$1,264
AbbVie(2 entities)87$1,247
Teva Pharmaceuticals USA, Inc.48$1,176
Neurocrine Biosciences, Inc.54$975
Amgen54$854
Acadia Pharmaceuticals Inc96$772
MDD US Operations, LLC11$497
Sunovion Pharmaceuticals Inc.76$481
SK Life Science, Inc.25$479
Pfizer46$472
Livanova USA, Inc.25$467
Kyowa Kirin, Inc.19$455
Eisai Inc.21$357
Lilly USA, LLC21$349
Biohaven Pharmaceuticals, Inc.22$331
AstraZeneca12$326
Argenx US, Inc.13$287
Catalyst Pharmaceuticals, Inc.15$265
Sanofi14$246
Biogen11$232
Neurelis, Inc.10$216
GE HealthCare11$215
Biohaven Pharmaceutical Holding Company Ltd.9$178
Supernus Pharmaceuticals, Inc.10$178
Octapharma USA, Inc.9$177
Johnson & Johnson6$139
Corium, LLC7$128
Lundbeck LLC5$85
Amneal Pharmaceuticals LLC5$80
Adamas Pharmaceuticals, Inc.5$79
Otter Pharmaceuticals, LLC2$73
Takeda Pharmaceuticals U.S.A., Inc.3$61
Abbott3$58
Avanir Pharmaceuticals, Inc.3$58
Sumitomo Pharma America, Inc.15$55
Avion Pharmaceuticals3$53
Impel Pharmaceuticals Inc.3$48
Greenwich Biosciences, Inc.2$42
Medtronic2$40
Upsher-smith Laboratories LLC2$39
CSL Behring2$39
Acorda Therapeutics, Inc2$37
ANI Pharmaceuticals, Inc.2$35
Bausch Health US, LLC2$34
Aquestive Therapeutics, Inc.2$28
E.r. Squibb & Sons, L.L.C.2$25
GRT US Holding, Inc.1$22
Averitas Pharma Inc.1$21
Promius Pharma LLC1$19
Sanofi Pasteur Inc.1$17
Currax Pharmaceuticals LLC1$14
Aprecia Pharmaceuticals, LLC1$14
Jazz Pharmaceuticals Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,281 in reported general payments places this provider in the 75th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$8,966
Medicare patients
37
Services billed
66

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine16$119,440
Gamunex-CImmune Globul G/Gly/Iga Avg 4611$102,409
NeuproRotigotine68$97,786
AptiomEslicarbazepine Acetate52$93,898
IngrezzaValbenazine Tosylate11$81,252
CopaxoneGlatiramer Acetate13$75,816
Aimovig AutoinjectorErenumab-Aooe42$70,119
NuplazidPimavanserin Tartrate12$55,822
Nurtec OdtRimegepant Sulfate28$36,549
QuliptaAtogepant29$33,826
BriviactBrivaracetam14$17,557
XcopriCenobamate11$11,742
OngentysOpicapone13$9,668
Lacosamide45$9,553
Emgality PenGalcanezumab-Gnlm12$8,973

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Copaxone$1,176$195,25629 claims
UCB, Inc.Neupro, Briviact$2,037$115,34382 claims
Sunovion Pharmaceuticals Inc.Aptiom$481$93,89852 claims
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$975$90,92024 claims
Acadia Pharmaceuticals IncNuplazid$772$55,82212 claims
PfizerNurtec Odt, Dilantin$472$38,16140 claims
AbbVieQulipta$1,247$33,82629 claims
SK Life Science, Inc.Xcopri$479$11,74211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,246 neurology providers in Texas.

Other neurology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →